Emerging evidence has suggested that dual incretin agonism with GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) could be more effective in the amelioration of MASLD [38,39]. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.